These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 27048870)

  • 1. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
    Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
    Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
    Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin receptor antagonists for pulmonary arterial hypertension.
    Liu C; Chen J; Gao Y; Deng B; Liu K
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
    Barnes H; Brown Z; Burns A; Williams T
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
    He CJ; Chen SJ; Wang J; Zhu CY; Yin YH
    Pulm Pharmacol Ther; 2015 Jun; 32():24-8. PubMed ID: 25843006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy in pulmonary arterial hypertension: a meta-analysis.
    Bai Y; Sun L; Hu S; Wei Y
    Cardiology; 2011; 120(3):157-65. PubMed ID: 22212696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
    Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R
    Respiration; 2016; 91(1):9-17. PubMed ID: 26492415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.
    Coeytaux RR; Schmit KM; Kraft BD; Kosinski AS; Mingo AM; Vann LM; Gilstrap DL; Hargett CW; Heidenfelder B; Dolor RJ; McCrory DC
    Chest; 2014 May; 145(5):1055-1063. PubMed ID: 24371842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis.
    Zhu B; Wang L; Sun L; Cao R
    J Cardiovasc Pharmacol; 2012 Oct; 60(4):342-6. PubMed ID: 22691882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.
    Ryerson CJ; Nayar S; Swiston JR; Sin DD
    Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
    Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Zhang HD; Zhang R; Jiang X; Sun K; Wu DC; Jing ZC
    Am Heart J; 2015 Jul; 170(1):96-103, 103.e1-14. PubMed ID: 26093869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
    Small M; Piercy J; Pike J; Cerulli A
    Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
    Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
    Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.